In particular, promising data revealed that fibroblast growth factor (FGF)-19, FGF-21 and leptin offer great potential for future clinical application in the treatment of obesity and related comorbidities. Here, FGF19 is linked to obesity due to melanocortin 4 receptor deficiency.